23-valent pneumococcal polysaccharide vaccine
- Generic Name
- 23-valent pneumococcal polysaccharide vaccine
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT05633992
- Locations
- 🇯🇵
PS Clinic ( Site 1002), Fukuoka, Japan
🇯🇵Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1006), Shinjuku-ku, Tokyo, Japan
🇯🇵Heishinkai Medical Group ToCROM Clinic ( Site 1004), Shinjuku-ku, Tokyo, Japan
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1484
- Registration Number
- NCT05569954
- Locations
- 🇩🇪
Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901), Hamburg, Germany
🇰🇷Asan Medical Center ( Site 1809), Seoul, Korea, Republic of
🇰🇷Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805), Seoul, Korea, Republic of
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2162
- Registration Number
- NCT05464420
- Locations
- 🇺🇸
L&C Professional Medical Research Institute ( Site 0012), Miami, Florida, United States
🇺🇸Desert Clinical Research/ CCT Research ( Site 0019), Mesa, Arizona, United States
🇺🇸Valley Clinical Trials, Inc. ( Site 0023), Northridge, California, United States
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 717
- Registration Number
- NCT05420961
- Locations
- 🇮🇱
Maccabi Health Services - Holon ( Site 0305), Holon, Israel
🇮🇱Maccabi Healthcare Services ( Site 0306), Jerusalem, Israel
🇮🇱Meir Medical Center ( Site 0301), Kfar Saba, Israel
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT05393037
- Locations
- 🇨🇱
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107), Santiago, Region M. De Santiago, Chile
🇿🇦Be Part Yoluntu Centre ( Site 0902), Paarl, Western Cape, South Africa
🇿🇦Josha Research ( Site 0900), Bloemfontein, Free State, South Africa
Persistent Readiness Through Early Prediction Immunization Study
- Conditions
- Inflammatory Response
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Texas A&M University
- Target Recruit Count
- 249
- Registration Number
- NCT05346302
- Locations
- 🇺🇸
Texas A&M University - CTRAL, College Station, Texas, United States
Vaccine Responses in Patients With B Cell Malignancies
- Conditions
- Lymphoma
- Interventions
- Biological: Heplisav -BBiological: Pfizer-COVID-19 VaccineBiological: FluLavalDrug: AREXVY, ABRYSVO
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 500
- Registration Number
- NCT05170399
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
- Conditions
- Pneumococcal Disease
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1425
- Registration Number
- NCT04875533
- Locations
- 🇯🇵
Seishinkai Inoue Hospital, Itoshima, Fukuoka, Japan
🇯🇵Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
🇯🇵Fukuwa Clinic, Chuo-ku, Tokyo, Japan
Effect of Obesity on Immune Response to Pneumovax 23
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 50
- Registration Number
- NCT02471014
- Locations
- 🇺🇸
Uf Ctsi Crc, Gainesville, Florida, United States
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 75
- Registration Number
- NCT02232191
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.